# FORWARD I (NCT02631876)

> A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02631876
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: ImmunoGen, Inc.
- Conditions: Epithelial Ovarian Cancer; Primary Peritoneal Carcinoma; Fallopian Tube Cancer; Ovarian Cancer
- Interventions: Mirvetuximab soravtansine; Paclitaxel; Pegylated liposomal doxorubicin; Topotecan
- Enrollment: 366
- Primary outcome: Progression-Free Survival (PFS), as Assessed by BIRC Per RECIST Version 1.1 in All Participants Randomized to the Study
- Primary outcome: PFS, as Assessed by BIRC Per RECIST Version 1.1 in Participants With High Folate Receptor Alpha Level (≥ 75% of Tumor Staining)

## Commentary we found

- Podcasts: 3
- YouTube: 2
- X threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=forward-i-nct02631876